GREGORY REINWALD: Open Payments
NPI 1265181010 · LATHAM, NY. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,631 in 68 payments from 18 companies in 2025. Trend: 2023 $0 · 2024 $712 · 2025 $1,631
Food & beverage: $1,631
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 14 | $309 |
| AstraZeneca Pharmaceuticals LP | 10 | $284 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 5 | $186 |
| Lilly USA, LLC | 9 | $176 |
| Novo Nordisk Inc | 7 | $157 |
| SANOFI-AVENTIS U.S. LLC | 2 | $86 |
| GlaxoSmithKline, LLC. | 4 | $81 |
| Lundbeck LLC | 2 | $61 |
| Abbott Laboratories | 3 | $59 |
| Astellas Pharma US Inc | 2 | $51 |
Products named: AIRSUPRA, JARDIANCE, UBRELVY, QULIPTA, ZEPBOUND, TZIELD, Wegovy, Ozempic.
Industry payments across NY — which companies pay providers there.
